Abeona Therapeutics Inc (ABEO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Abeona Therapeutics Inc (ABEO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7331
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in Dallas, Texas, the US.

Abeona Therapeutics Inc (ABEO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Abeona Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Abeona Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Abeona Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Medical Equipment, Deal Details 10
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 10
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 11
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 13
Equity Offering 14
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 14
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 15
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 17
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 19
Abeona Therapeutics Inc – Key Competitors 20
Abeona Therapeutics Inc – Key Employees 21
Abeona Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 09, 2018: Abeona Therapeutics reports second quarter 2018 financial results and business highlights 23
May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights 25
Mar 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights 27
Nov 15, 2017: Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights 28
Aug 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 29
May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 31
Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 33
Corporate Communications 35
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 35
May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors 36
Apr 02, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer 37
Jul 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer 38
Legal and Regulatory 39
Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 39
Product News 40
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 40
Jun 06, 2018: Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference 41
Other Significant Developments 42
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Abeona Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Abeona Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Abeona Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Abeona Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 10
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 11
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 13
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 14
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 15
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 17
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 19
Abeona Therapeutics Inc, Key Competitors 20
Abeona Therapeutics Inc, Key Employees 21
Abeona Therapeutics Inc, Subsidiaries 22

List of Figures
Abeona Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Abeona Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Abeona Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Abeona Therapeutics Inc (ABEO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PolyPid Ltd:製品パイプライン分析
    Summary PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipelin …
  • Poxel SA (POXEL):製薬・医療:M&Aディール及び事業提携情報
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • Warisan TC Holdings Berhad:企業の戦略・SWOT・財務情報
    Warisan TC Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Warisan TC Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Aphios Corp-製薬・医療分野:企業M&A・提携分析
    Summary Aphios Corp (Aphios) is a biotechnology company that develops nanotechnology drug delivery platforms. The company provides technology platforms and enhanced therapeutics for the treatment of infectious diseases, cancers and central nervous system disorders. Its therapeutic products include Z …
  • SFS Group AG:企業の戦略・SWOT・財務分析
    SFS Group AG - Strategy, SWOT and Corporate Finance Report Summary SFS Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Finning International Inc (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Transgene SA (TNG):企業の財務・戦略的SWOT分析
    Summary Transgene SA (Transgene) a subsidiary of Institut Merieux SA operates as a biotechnology company that offers discovery and development of immunotherapies in the areas of cancer and infectious diseases. The company offers products such as therapeutic vaccines and oncolytic viruses. It develop …
  • AGL Energy Ltd (AGL):石油・ガス:M&Aディール及び事業提携情報
    Summary AGL Energy Limited (AGL) is an integrated energy company that owns, operates and develops energy assets and provides natural gas, electricity, solar photovoltaic solutions and related products and services. The company’s power generation portfolio includes coal, gas, hydro, wind, solar, land …
  • Ecology and Environment Inc (EEI):企業の財務・戦略的SWOT分析
    Summary Ecology and Environment Inc (E&E) is an environmental consultancy service provider. The company provides air quality, cultural resources, emergency planning: mitigation and prevention, preparedness, and response and recovery, and water resources planning; climate and sustainable development; …
  • Ablynx NV (ABLX)-製薬・医療分野:企業M&A・提携分析
    Summary Ablynx NV (Ablynx) is a clinical-stage biopharmaceutical company focused on the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional …
  • Da Afghanistan Breshna Sherkat:企業の戦略的SWOT分析
    Da Afghanistan Breshna Sherkat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • TIVIT Terceirizacao de Tecnologia e Servicos SA:企業の戦略的SWOT分析
    TIVIT Terceirizacao de Tecnologia e Servicos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Rajesh Exports Limited:企業の戦略・SWOT・財務情報
    Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report Summary Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • 3i Group Plc:企業のM&A・事業提携・投資動向
    3i Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3i Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • JHL Biotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary JHL Biotech Inc (JHL Biotech) is a biologic medicines provider. The company offers cell line construction, process development, manufacturing, quality and regulatory services. It offers products such as biosimilar rituximab, biosimilar dornase alfa, biosimilar bevacizumab, biosimilar trastuz …
  • PDS Biotechnology Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary PDS Biotechnology Corp (PDS Biotechnology) is a biopharmaceutical company that develops vaccines and immunotherapies for cancer and infectious disease. The company uses versamune technology that is immunostimulatory nanoparticle vaccine platform used for the development of cancer immunothera …
  • E*Trade Financial Corp:企業の戦略・SWOT・財務情報
    E*Trade Financial Corp - Strategy, SWOT and Corporate Finance Report Summary E*Trade Financial Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Luxottica Group S.p.A.:企業の戦略・SWOT・財務情報
    Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Dimension Data Holdings Plc:企業の戦略的SWOT分析
    Dimension Data Holdings Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Mitsubishi Motors Corporation (7211):企業の財務・戦略的SWOT分析
    Mitsubishi Motors Corporation (7211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆